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Abstract
Introduction: The purpose of this study was to examine the role of RA Synovial Fibroblast (RASFib) IL-15 expression on B cell
survival.
Methods: Magnetically sorted peripheral blood memory B cells from 15 healthy subjects were cocultured with RASFib.
Results: RASFib constitutively expressed membrane IL-15. Survival of isolated B cells cultured for 6 days, below 5%, was
extended in coculture with RASFib to 52+/28% (p,0.001). IL-15 neutralizing agents but not isotype controls, reduced this
rate to 31+/26% (p,0.05). Interestingly, rhIL-15 had no effect on isolated B cells but significantly increased their survival in
coculture with RASFib. In parallel, B cell IL-15R chains were upregulated in cocultures. BAFF and VCAM-1, that are expressed
on RASFib, were tested as potential candidates involved in upregulating B cell IL-15R. Culture of B cells in the presence of
rhBAFF or rhVCAM-1 resulted in significantly increased survival, together with upregulation of all three IL-15R chains; in
parallel, rhIL-15 potentiated the anti-apoptotic effect of BAFF and VCAM-1. Both BAFF and VCAM-1 neutralizing agents
downmodulated the effect of RASFib on B cell survival and IL-15R expression. In parallel, rhIL-15 had a lower effect on the
survival of B cells cocultured with RASFib in the presence of BAFF or VCAM-1 neutralizing agents. Peripheral blood B cells
from 15 early RA patients demonstrated an upregulated IL-15R and increased survival in cocultures.
Conclusion: IL-15 expression on RASFib significantly contributes to the anti-apoptotic effect of RASFib on B cells. IL-15
action is facilitated by BAFF and VCAM-1 expressed on RASFib, through an upregulation of IL-15R chains.
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Introduction
The inflamed synovium of Rheumatoid Arthritis (RA) is
characterized by a hyperplastic lining layer of macrophages and
fibroblasts (RASFib) [1]. In addition, the adjacent sublining layer
contains an infiltrate of myeloid and lymphoid cells that in most
patients is diffuse, with immune cells randomly distributed among
resident fibroblasts and endothelial cells [2]. Alternatively in some
20% of patients, T and B cells are arranged in defined follicles
designated as aggregates and yet in rarer cases, infiltrating
lymphoid cells form ectopic germinal centers [3].
B cells can contribute to the pathogenesis of RA synovitis
through the local production of antibodies [4], chemokines and
cytokines, and acting as efficient antigen presenting cells (APCs)
[5]. The mechanisms leading to B cell accumulation in the RA
synovium are not fully understood, and several reports have
demonstrated a pivotal role of direct B cell/RASFib interactions
[6–11]. In fact, infiltrating B lymphocytes and plasma cells have
been observed in close contact with RASFib in the subintimal
layer [6]. Furthermore, RASFib seem to have properties of FDCs
[7], and express B cell trophic factors such as VCAM-1 [8–10] and
BAFF [11–13]. In addition, IL-15 expression has been observed in
the intimal and subintimal layer of the RA synovial membrane
[14], is transiently upregulated in the synovial fluid of early RA
patients [15], and we have reported that constitutively expressed
IL-15 on the surface of RASFib is biologically active on cocultured
T lymphocytes through direct cell contact [16,17].
The cytokine IL-15 shares many properties with IL-2 [18] and
acts through a heterotrimeric receptor consisting of a specific high-
affinity binding a-chain (designated as IL-15Ra) plus the IL-2Rb-
and common c-chain, that are responsible for signaling [19,20].
Armitage et al first described in 1995 that IL-15 costimulates the
proliferation and differentiation of activated B cells, but has no
stimulatory effect on resting B cells [21], and it has more recently
been reported that IL-15 on the surface of follicular dendritic cells
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enhances germinal center B cell proliferation [22]. Therefore, our
objective was to examine the effect of RASFib IL-15 on peripheral
blood B cells.
Circulating peripheral blood B cells from untreated, early RA
patients are likely to be activated and display heightened responses
when cocultured with RASFib. Our early arthritis clinic allowed
the study of B cells from early RA patients who have not received
disease modifying drugs (DMARDs) or steroids, thereby minimiz-
ing interference of drugs with in vitro B cell responses.
We observed that IL-15 expression on RASFib significantly
promoted the survival of cocultured B cells. Interestingly, the
action of IL-15 was facilitated by BAFF and VCAM-1 expressed
on RASFib, through an upregulation of IL-15R chains. In
addition, peripheral blood B cells from early RA patients
demonstrated a constitutively upregulated expression of IL-15R
chains together with and increased survival rate in cocultures.
Methods
Ethics Statement
The study was approved by the Hospital La Paz – IdiPAZ
Ethics Committee, and all subjects provided written informed
consent.
Patients
Synovial membranes were obtained from 10 RA patients with
established disease undergoing synovectomy or arthroplasty, and
from 10 osteoarthritis (OA) patients undergoing arthroplasty
(Table 1). Peripheral blood was obtained from 15 healthy controls
and from 15 early RA patients fulfilling at least four American
College of Rheumatology criteria [23], who had never received
disease-modifying drugs or corticosteroids and with a disease
duration of ,6 months (Table 2). La Paz University Hospital in
Madrid, Spain, has a monographic clinic that takes care of early
arthritis patients referred from a wide primary care area. This
facilitated recruitment of untreated early RA patients for the
present study. Among early RA patients there were 3 male and 12
female, 13 (87%) tested positive for IgM rheumatoid factor, their
ages were 23–76 years (mean 49.72, SD 15.52, median 46),
duration of symptoms at first evaluation was from 2 to 24 wk
(mean 9.23, SD 5.7, median 8.8), and disease activity score 28
(DAS28) [24] at first evaluation was from 4.95 to 7.76 (mean 5.85,
SD 0.81, median 5.59) (Table 2). Eight patients with early RA
donated blood for a second time, once disease activity had been
controlled. These patients were receiving 15 mg of oral MTX
weekly, except for one patient who was taking 20 mg per week.
Additionally, 2 patients were taking prednisone, 2.5 mg daily. IgM
rheumatoid factor was positive at initial evaluation in 7 of these 8
patients; there were 1 man and 7 women, with ages of
41.52611.39 years (mean6SD). DAS28 before initiation of
treatment was 5.9260.77 (mean6SD) and at the time of the
second blood drawing it was 1.9160.4. These patients were in
remission as defined by a DAS28 score ,2.6 [25] (Table 2).
Culture of Human Fibroblasts
RASFib and OASFib were obtained by collagenase digestion
(type I; Worthington Biochemical, Freehold, NJ) of human
synovial tissue obtained at arthroplasty or synovectomy. Dermal
fibroblasts were obtained by collagenase digestion of normal skin
obtained from punch biopsies of five healthy volunteers. Cells were
plated in 75-cm2 flasks (Corning Life Sciences, Amsterdam, The
Netherlands) and grown in DMEM (Lonza, Basel, Switzerland)
supplemented with 10% FCS (Lonza), 2 mM L-glutamine, 50 U/
ml penicillin, and 50 mg/ml streptomycin (Lonza). Cells were
passaged at 1/2 dilution when reaching 95% confluence, by gentle
trypsinization (0.05% trypsin/0.53 mM EDTA; Gibco-Invitrogen,
Carlsbad, CA). Fibroblasts were used between the third and fifth
passages. At this time, they appear to be a homogeneous
population of fibroblast-like cells that stain positive with anti-
Thy-1 (CD90) Ab [26] and are negative for the expression of CD1,
CD3, CD19, CD14, HLA class II, CD80, and CD86, as
determined by flow cytometry and fluorochrome-conjugated
monoclonal antibodies (BD Pharmingen, San Jose, CA)
(Figure 1A, B).
Memory B Cell Purification
Peripheral blood mononuclear cells (PBMCs) were separated
from the peripheral blood by Ficoll-Paque Plus (GE Healthcare,
Uppsala, Sweden) density gradient centrifugation. Highly
purified B cells were isolated from PBMCs by exhaustive
immunomagnetic depletion in an Automacs (Miltenyi Biotec,
Bergisch Gladbach, Germany) using the ‘‘B Cell Isolation Kit
II’’ (Miltenyi Biotec), containing a cocktail of biotin-conjugated
antibodies against CD2, CD14, CD16, CD36, CD43, CD235a
(Glycophorin A), and anti-biotin microbeads. Purity of B cells as
assessed by flow cytometry was .99% CD19+. Subsequently,
memory B cells (CD19+CD27+) were positively selected using
CD27+ microbeads (Miltenyi Biotec), and purity of
CD19+CD20+CD27+ cells by flow cytometry was $98%
(Figure 1C). Memory B cells were used immediately after
isolation. Memory B cells will henceforth be referred to as ‘‘B
cells’’.
Culture of Isolated B Cells
Isolated memory B cells were cultured in 96-well flat-bottom
plates (Corning) (105 cells/well) with RPMI 1640 medium (Lonza)
containing 10% FCS, 2 mM L-glutamine, 50 U/ml penicillin,
50 mg/ml streptomycin and 50 mM 2-mercapto-ethanol (‘‘com-
plete RPMI medium’’). In some conditions, medium was
supplemented with recombinant human IL-15 (rhIL-15), 1 to
400 ng/ml (R&D Systems, Abingdon, U.K.) or with rhBAFF, 1 to
400 ng/ml (R&D Systems). For VCAM-1 stimulation experi-
ments, flat-bottom 96-well plates were coated with 10 mg/ml
rhVCAM-1 (R&D Systems) for 1 hour at 37uC; memory B cells
were subsequently cultured on coated wells in complete RPMI
1640 medium.
Coculture Conditions
Experiments were performed with confluent fibroblast cul-
tures prepared three days before contact. All experimental
conditions were performed in triplicate and variation between
Table 1. Clinical data of patients providing surgical synovial
samples.
Established RA OA
Number 10 10
Age (mean 6 SD) 68+ 70+
Gender (Male/Female) 2/8 3/7
Disease duration (mean 6 SD) 1766 years 1265 years
Rheumatoid factor + 8 (80%) 0 (0%)
Anti-CCP + 7 (70%) 0 (0%)
DAS28 (mean 6 SD) 3.660.6 N/A
doi:10.1371/journal.pone.0040620.t001
RA Fibroblast IL-15 Promotes B Cell Survival
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Table 2. Clinical data of early RA patients at first evaluation and of early RA patients (8 out of 15) who donated blood for a second
time, once remission had been achieved.
Early RA (1st evaluation) Early RA (2nd evaluation)
Number 15 8
Age (mean 6 SD) 49.72615.52 yrs 41.52611.39
Gender (Male/Female) 3/12 1/7
Disease duration (mean 6 SD) 9.2365.7 weeks 16.261.5 months
Rheumatoid factor + (%) 13 (86.7%) 7 (87.5%)
Anti-CCP + (%) 11 (73%) 6 (75%)
DAS28 (mean 6 SD) 5.8560.81 1.9160.4
Medication NSAIDs Oral MTX6PRD
doi:10.1371/journal.pone.0040620.t002
Figure 1. Characterization of cultured RASFib, OASFib and dermal fibroblasts (Third passage) and of freshly isolated memory B
cells. A. Representative flow cytometry histograms show staining of cultured RASFib (Third passage) with anti-CD90, anti-CD1, anti-CD3, anti-CD19,
anti-CD14, anti-HLA-DR, anti-CD80 and anti-CD86 (Thick lines) or appropriate isotype controls (Thin lines). B. Bar histogram showing the MFI of
RASFib (n = 10 lines), OASfib (n = 10 lines) or dermal fibroblasts (n = 5 lines) on the thrid passage, after staining with the antibodies mentioned in A. C.
Representative flow cytometry dot plots after triple staining of isolated memory B cells with anti-CD20 FITC, anti-CD19 APC and anti-CD27PE or
isotype control (gamma1) PE. Shown are two-dimension dot plots with different combinations of the above mentioned fluorochrome-labeled
antibodies.
doi:10.1371/journal.pone.0040620.g001
RA Fibroblast IL-15 Promotes B Cell Survival
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replicates was ,5%. RASFib were seeded in 96-well flat-bottom
plates at 56103 cells/well. Three days later, the separated
memory B cells (16105 cells/well) were added in fresh complete
RPMI medium. B cells were harvested after 24, 48, 72 h, 4, 5
and 6 days by thorough washing with cold, serum-free medium.
In some experiments, rhIL-15 (50 ng/ml) was added right after
initiating cocultures.
Transwell system. A 0.4- mm Transwell system (Corning)
was used to conduct some coculture experiments. The system
consists of two compartments: a top well, with a porous matrix
(0.4 mm), and a bottom well. This setup allows coculture of two
types of cells to grow in the same medium with soluble factors
exchanged through the pores, while preventing direct contact
between them. RASFib were grown to confluence in the bottom
well, and B cells were added either to the same well, allowing
contact, or in the top well, avoiding contact.
Assessment of Cell Viability
Cell viability was assessed by flow cytometry after staining with
10 mM JC-1 (5,59,6,69-tetrachloro-1,19,3,39-tetraethylbenzimida-
zol-carbo-cyanine iodide, Molecular Probes - Invitrogen, Leiden,
The Netherlands) to evaluate the mitochondrial membrane
potential or with annexin V/7AAD (7-Amino-actinomycin D)
(BD PharMingen) to evaluate plasma membrane integrity,
according to the manufacturers’ instructions.
Neutralization Assays
Parallel experiments included the addition of blocking agents
against IL-15, BAFF or VCAM-1: a neutralizing anti-IL-15 mAb
(10 mg/ml; mab247, mouse IgG1; R&D Systems), a recombinant
IL-15Ra/human Fcc1 chimera (100 ng/ml; 147-IR, R&D
Systems), an IL-15 mutant/murine Fcc2a chimera, which is a
high-affinity receptor site-specific antagonist for IL-15Ra [27],
(10 mg/ml; HF 22015, Chimerigen, Allston, MA), an anti-BAFF
mAb (5 mg/ml; mab124, mouse IgG2b, R&D systems) or an anti-
VCAM-1 mAb (30 mg/ml; BBA6, mouse IgG1, R&D systems). In
addition, the binding control anti-HLA class I (clone W6/32,
10 mg/ml; Sigma-Aldrich), or appropriate isotype controls (murine
IgG1, murine IgG2a, murine IgG2b or human IgG1; all from
R&D Systems) were used. These Abs were incubated with RASFib
for 30 min at 37uC, and B cells were subsequently added without
washing.
Surface Cell Staining and Flow Cytometry
For surface IL-15 staining, RASFib were harvested on ice with
PBS/5mM EDTA, washed with PBS/2% FCS/0.01% NaN3, and
incubated on ice for 1 h with an anti-IL-15 mAb (mab 2471, R&D
systems) or an irrelevant isotype control mAb. After further
washing with PBS/2% FCS/0.01% NaN3, cells were incubated
with an Alexa Fluor 488-goat anti-mouse Ab, washed once with
PBS/2%FCS/0.01% NaN3 and once with PBS. Cells were then
resuspended in 1% paraformaldehyde and analyzed in a
FACSCalibur flow cytometer using CellQuest software (BD
Biosciences). Surface IL-15Ra and surface BAFF were detected
with an anti-IL-15Ra mAb (R&D Systems) or an anti-BAFF mAb
(both from R&D systems), followed by an Alexa Fluor-488 or an
Alexa Fluor-647 goat anti-mouse affinity purfied Ab (both from
Molecular Probes/Invitrogen ). VCAM-1, IL-15 receptor b, and
common c chain were detected with PE-labeled anti-VCAM-1,
PE-labeled anti-IL-2/IL-15Rb (CD122), or PE-labeled anti-
common c chain (CD132) versus a PE-labeled isotype-matched
control mAb (all from BD PharMingen, San Jose´, CA).
Fluorochrome-conjugated mAbs from BD PharMingen were used
to examine the expression of the phenotypic markers CD19,
CD20, CD27, CD1, CD3, CD14, HLA DR, CD80, and CD86.
Mean fluorescence intensity (MFI) values are given as the
difference between the MFI of tested cells and the MFI of
background staining. Fold of induction for IL-15 receptor chains
was calculated as ‘‘MFI of cocultured or treated cells/MFI freshly
isolated cells’’.
Soluble Cytokine Detection
ELISAs for BAFF and IL-15 were performed in cell-free
supernatants using kits from R&D Systems, Abingdon, UK,
following the manufacturer’s instructions.
Quantitative RT-PCR
For RNA extraction, B cells were collected as described above.
Contamination by RASFib was ruled out by flow cytometry and
by the absence of amplification of typical RASFib markers by RT-
PCR, such as CD 90 (Thy-1). Total cellular RNA was isolated
using the RNAQueous kit (Ambion-Applied Biosystems, Austin,
TX) with DNAse treatment. For each sample, 1 mg of total RNA
was subjected to reverse transcription using an Advantage RT for
PCR kit (BD-Clontech, Palo Alto, CA), according to the
manufacturers instructions. Aliquots (1 ml) of the reverse tran-
scription products were used for quantitative PCR in the
LightCyclerTM PCR and Detection System (Roche Molecular
Biochemicals, Mannheim, Germany) using the FastStart DNA
Master SYBR Green I kit (Roche Diagnostics) as described by the
manufacturer. The PCR reactions were set up in microcapillary
tubes in a volume of 20 ml. The following sense and antisense
primers were used: IL-15Ra primers are located in exon 2 (sense)
and exon 5 (antisense) to amplify mRNA encoding all IL-15Ra
variants that contain exon 2, and thus, bind IL-15: IL-15Ra sense
59- GGA ATT CAT CAC GTG CCC TCC CCC CAT G -39; IL-
15Ra antisense, 59- CGG GAT CCT CAA GTG GTG TCG
CTG TGG CCC TG –39 (product size, 543/444). IL-2/IL15Rb
sense, 59- ACC TCT TGG GCA TCT GCA GC- 39; IL-2/
IL15Rb antisense 59- CGT CTC CAG GCA GAT CCA TT –39
(product size, 531); common c chain sense 59- CCA GAA GTG
CAG CCA CTA TC- 39, common c chain antisense 59- TCA
CTC CAA TGC TGA GCA CT –39 (product size, 420).
Quantitative PCR was performed in triplicate as previously
described [15]. As an external standard, the transcript of 18S
rRNA was amplified from the same cDNA samples using primers
manufactured by Ambion. Quantities of specific mRNA in the
sample were measured according to the corresponding gene-
specific standard curve. The results are expressed as fold of
induction: (cDNA sample cultured cells/18S cultured cells)/
(cDNA sample freshly isolated cells/18S freshly isolated cells).
Statistical Analysis
Comparison between groups was by Mann-Whitney U test.
Paired samples were compared using a Wilcoxon matched pairs
signed rank sum test. When appropriate, Bonferroni correction for
multiple comparisons was applied.
Results
Effect of RASFib on B Cell Survival
The percentage of viable B cells obtained afer staining with JC-1
or annexinV/7AAD were comparable (Figure 2A), and results
using JC-1 are shown henceforth throughout the manuscript.
When compared with freshly isolated B cells (98,660.7%
viability), viability of B cells cultured in plain medium dramatically
decreased over time (3.661.9% viability on the 6th day) (Figure 2A,
B). Coculture with RASFib significantly improved B cell survival
RA Fibroblast IL-15 Promotes B Cell Survival
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Figure 2. Effect of RASFib on B cell survival. Coculture with RASFib significantly increases B cell survival in a cell-contact dependent manner. A.
Representative flow cytometry dot-plots of B cells stained with JC-1 or with 7AAD/Annexin V. When compared with freshly isolated B cells, viability of
B cells cultured in plain medium for 6 days is dramatically decreased. Coculture with RASFib for 6 days significantly improves B cell survival. B.
Percentage of viable B cells at different time points (0 to 6 days) (JC-1 staining). B cells were cultured in plain medium or cocultured with untreated
RA Fibroblast IL-15 Promotes B Cell Survival
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(53,268.1% viability on the 6th day) (p,0.01) (Figure 2A, B). This
effect was cell-contact dependent: when cocultures were estab-
lished in the presence of transwell inserts that do not allow contact
between B cells and fibroblasts, B cell survival was very short, as
observed in isolated B cell cultures (Figure 2B), and significantly
lower than survival observed when direct contact between B cells
and fibroblasts was allowed (Figure 2B). Furthermore, the addition
of supernatants from 6 day RASFib/B cell cocultures to isolated B
cells did not increase survival (Figure 2B).
RASFib were significantly more effective than OASfib or
dermal fibroblasts at promoting B cell suvival (Figure 2C), as
indicated by the percentage of viable cells present at 6 days
cocultures of B cells with RASFib versus cocultures with OA or
dermal fibroblasts, versus B cells cultured alone. All of the tested
RA synovial fibroblast lines had comparable effects on B cell
survival (Figure 2D); likewise, variations among different OASFib
lines and dermal fibroblast lines were also small when comparing
their effects on B cell viability (Figure 2D).
Effect of IL-15 Neutralizing Agents on the Survival of B
Cells Cocultured with RASFib
As previously described [15], RASFib but not OASFib or
dermal fibroblasts, constitutively expressed IL-15 on the cell
membrane (Figure 3A). In contrast, the concentration of soluble
IL-15 in cell-free supernatants was very low: 4.261.5 pg/ml. Of
note, exogenous recombinant human IL-15 had a minimal effect
on B cell survival at doses of 50 ng/ml and above and no effect at
doses below 50 ng/ml ( = 50,000 pg/ml) (Figure 3B).
IL-15 neutralizing agents significantly reduced the survival of B
cells cocultured with RASFib (Figure 3C,D). All of the three tested
IL-15 neutralizing agents were effective: an antagonistic IL-15
mutant/Fcc2a fusion protein that binds to the IL-15 receptor but
does not induce signal transduction [25], an IL-15Ra-Fc fusion
protein and a neutralizing anti-IL-15 mAb (Figure 3C,D). In
contrast, B cell survival was not modified in the presence of isotype
control agents or in the presence of the binding control anti-HLA
class I (W6/32) (Figure 3C,D). Neutralization of IL-15 had no
effect on the life span of B cells cocultured with OASFib or dermal
fibroblasts (Figure 3C).
Effect of RASFib on IL-15R Expression
Interestingly, whereas exogenous recombinant human IL-15 (1–
400 ng/ml) had a minimal effect on B cell survival when added to
isolated B cells in culture (Figure 3B), in the presence of RASFib,
recombinant human IL-15 (50 ng/ml) significantly increased B
cell survival above that observed in cocultures established in plain
medium (Figure 3E).
Therefore we next sought to examine the expression of IL-15R
on freshly isolated B cells and on B cells cocultured with RASFib
(Figure 4). B cells cocultured with RASFib significantly upregu-
lated IL-15 Ra, b and c chain expression at the mRNA (Figure 4A)
and protein levels (Figure 4 B, C). This indicates that RASFib
facilitate the action of IL-15 on B cells through an upregulation of
B cell IL-15R chains.
Effect of BAFF and of VCAM-1 on B Cell Expression of IL-
15R and on the Survival of B Cells Cocultured with
RASFib
Consistent with previous reports [8–13], RASFib but not
OASFib or dermal fibroblasts, demonstrated a significant consti-
tutive surface expression of the B cell survival factors VCAM-1
and BAFF (Figure 5A). In contrast, suboptimal levels of soluble
BAFF were present in cell-free supernantants of RASFib
(mean6SD, 3865 pg/ml). In fact, soluble rhBAFF had no effect
on B cells when tested at concentrations below 10 ng/ml
(Figure 5B). This observation is consistent with above presented
results, showing that supernatants of RASFib/B cell cocultures
had no effect on the survival of isolated B cells. Therefore we were
next interested in examining the possible role of membrane BAFF
and VCAM-1 in the RASFib-mediated upregulation of B cell
IL15-R chains, and in facilitating the effect of RASFib IL-15 on B
cell survival.
B cells cultured in the presence of high concentrations of
exogenous rhBAFF (100 ng/ml) or in the presence of plate-bound
rhVCAM-1 demonstrated an improved survival rate at 6 days,
when compared with B cells cultured in plain medium (Figure 5C).
Interestingly, whereas the effect of isolated rhIL-15 on B cell
viability was minimal (Figure 3B, 5C), the increased survival rate
of B cells stimulated with rhBAFF or rhVCAM-1 was further
augmented in the presence of rhIL-15 (50 ng/ml) (Figure 5C). In
parallel, an upregulation of IL-15R chains was observed on B cells
cultured in the presence of rhBAFF or of rhVCAM-1 (Figure 5D).
We next observed that the anti-apoptotic effect of RASFib on B
cells was significantly reduced in the presence of anti-BAFF or
anti-VCAM-1 neutralizing antibodies (Figure 5E). Combination of
anti-BAFF or anti-VCAM-1 with anti-IL-15 further decreased the
survival of B cells cocultured with RASFib (Figure 5E). In
addition, anti-BAFF or anti-VCAM-1 neutralizing antibodies
significantly decreased the facilitating effect of RASFib on IL-15
action (Figure 5E). In parallel, neutralization of BAFF or of
VCAM-1 significantly reduced the upregulated IL-15R a, b and c
chain expression induced on B cells by coculture with RASFib
(Figure 5F). Neutralization of VCAM-1 or BAFF had no effect on
the suvival of B cells cocultured with OASFib or dermal fibroblasts
(Figure 5G ).
Memory B Cells from the Peripheral Blood of Early RA
Patients Demonstrate Higher Levels of IL-15R Expression
Together with Superior Survival Rates in Response to
rhIL-15 and in Coculture with RASFib
When compared with memory B cells from the peripheral blood
of healthy controls, the MFI of IL-15R a, b and c chain expression
was significantly higher on memory B cells isolated from the
peripheral blood of early RA patients (Figure 6A). When
stimulated with rhIL-15 in the absence of RASFib, the survival
of RA memory B cells was significantly increased as compared
with RA memory B cells cultured in plain medium, and opposed
to memory B cells from healthy controls which showed a lower
response to rhIL-15 (Figure 6B). In B cell/RASFib cocultures, the
RASFib, with RASFib and transwell inserts, or cultured with supernatants from 6-day RASFib/Bcell cocultures. Each point represents the mean and SD
of 15 subjects. * p,0.05 vs B cells cultured in plain medium. C. RASFib are significantly more effective than OASFib or dermal fibroblasts at promoting
B cell suvival. Shown is the percentage of viable cells present at 6 days cocultures of B cells with RASFib versus cocultures with OA or dermal
fibroblasts, versus B cells cultured alone (JC-1 staining). Each bar represents the mean and SD of 15 subjects per group. *p,0.05 vs B cells cultured
alone in plain medium; {p,0.05 vs B cells cocultured with RASFib. D. Variation of the effect of different RA, OA or dermal fibroblast cell lines on B cell
survival was small. B cells from a single donor were cocultured for 6 days with 10 different RA synovial fibroblast lines (RA 1-10), 10 different OA
synovial fibroblast lines (OA 1-10) or 5 different dermal fibroblast lines (Der 1–5). Shown is the percentage of viable B cells on the 6th day of coculture
with each of the tested lines (JC-1 staining).
doi:10.1371/journal.pone.0040620.g002
RA Fibroblast IL-15 Promotes B Cell Survival
PLoS ONE | www.plosone.org 6 July 2012 | Volume 7 | Issue 7 | e40620
RA Fibroblast IL-15 Promotes B Cell Survival
PLoS ONE | www.plosone.org 7 July 2012 | Volume 7 | Issue 7 | e40620
Figure 3. Effect of IL-15 neutralizing agents and of exogenous rhIL-15 on the survival of B cells cocultured with RASFib. The effect of
RASFib on B cell survival is modified by IL-15 neutralizing agents and by exogenous rh IL-15. A. Flow cytometry of non-permeabilized cells
demonstrates surface IL-15 expression on RASFib, OASFib and dermal fibroblasts. Top panels: representative flow cytometry histograms. Lower panel:
bar histogram showing the mean and SD of the MFI (mean fluorescence intensity) of all tested RASFib cell lines (n = 10), OASFib lines (n = 10) and
dermal fibroblast lines (n = 5). B. Effect of rhIL-15 (1–400 ng/ml) on isolated B cells cultured alone for 6 days. Each point represents the mean and SD
of 15 subjects. C. Effect of IL-15 neutralizing agents on the survival of B cells cocultured with RASFib, OASFib or dermal fibroblasts (single time point,
6th day of coculture). Each point represents the mean and SD of 15 subjects. * p,0.05 vs same condition in the absence of neutralizing agents.
{p,0.05 vs B cells cocultured with RASFib in the absence of IL-15 neutralizing agents. D. Effect of IL-15 neutralizing agents on the survival of B cells
cocultured with RASFib. Time-course (0–6 day coculture). Each point represents the mean and SD of 15 subjects. * p,0.05 vs conditions in the
absence of neutralizing agents. E. rhIL15 has a minimal effect on the survival of B cells cultured alone but significantly upregulates the survival of B
cells cocultured with RASFib. Each point represents the mean and SD of 15 subjects. *p,0.05 vs B cells cultured in plain medium. { p,0.05 vs B cells
cultured with RASFib in the absence of rhIL-15.
doi:10.1371/journal.pone.0040620.g003
Figure 4. Effect of RASFib on the expression of IL15R a, b and c chains on cocultured B cells. B cells cocultured with RASFib upregulate IL-
15 a, b and c chain expression. A. Real-time quantitative analysis of IL-15R mRNA expression in B cells cocultured with RASFib for 24, 36 or 48 h.
Shown is fold of induction referred to expression of IL-15R a, b and c chain in freshly isolated B cells. Each bar represents the mean and SD of 15
subjects. B. Expression of IL-15R a, b and c chain on the surface of non-permeabilized B cells as determined by flow cytometry. Shown is expression
on freshly isolated B cells, on B cells cocultured with RASFib for 3 days and on B cells cocultured with RASFib for 6 days. Each bar represents the mean
and SD of 15 subjects. *p,0.05 vs freshly isolated B cells (day 0); { p,0.05 vs B cells cocultured for 3 dys with RASFib (day 3). C. Representative flow
cytometry histograms showing the expression of IL-15R a, b and c chains on freshly isolated B cells and on B cells cocultured with RASFib for 3 or 6
days.
doi:10.1371/journal.pone.0040620.g004
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survival rate of memory B cells from the peripheral blood of early
RA patients was significantly higher when compared with healthy
controls (Figure 6B). In the presence of IL-15 neutralizing agents,
the effect of RASFib on RA memory B cell survival was
significantly downregulated. The magnitude of this downmodula-
tion was higher when compared with that observed in memory B
cells from healthy controls. Subsequently, in the presence of
RASFib and of IL-15 neutralizing agents, no difference was
observed between the survival rate of RA memory B cells and the
survival rate of memory B cells from healthy controls, suggesting
that IL-15 plays an important role in the superior survival rate of
cocultured RA memory B cells.
Interestingly, when memory B cells from 8 of the 15 early RA
patients were re-examined in a follow-up visit, after remission had
been achieved with treatment (oral methotrexate with or without
low-dose prednisone) (Table 2), their IL-15R expression and their
behaviour in coculture with RASFib were no longer different from
healthy controls (Figure 6A, B).
Discussion
We have herein shown for the first time that IL-15 expression
on RASFib significantly contributes, through a cell-contact
dependent mechanism, to the previously described anti-apoptotic
effect of RASFib on B cells [6–11].
IL-15, initially described as a T cell growth factor [19,28], has
been reported to costimulate the proliferation and differentiation
of activated B cells [21]. IL-15 acts through a heterotrimeric
receptor consisting of a specific high-affinity binding a-chain (IL-
15Ra) plus the IL-2 receptor subunits b- and common c-chain
that mediate signalling [29,30]. The high affinity of IL-15Ra
conditions an extremely rapid uptake of secreted IL-15, thereby
preventing detection of IL-15 in culture supernatants [31].
Subsequently, most of the IL-15 detected on cell surfaces is bound
to IL-15Ra [31] and can stimulate in trans both bc- and IL-15R-
abc- bearing cells [31]. The presence of surface IL-15Ra-bound
IL-15 is synonimous of active IL-15 secretion, and the level of
expression of surface IL-15 in a given cell population may reflect
the rate of internalization of the IL-15/IL-15Ra complex. Thus,
in contrast with IL-2, IL-15 can be expressed on the cell surface,
where it is able to exert biological functions through cell contact-
dependent mechanisms [29–31]. IL-15 is expressed intracellularly
by monocyte-macrophages [29,30], dendritic cells [29,30] and fi-
broblasts [30,32]. Surface IL-15 is constitutively present and
physiologically active on follicular dendritic cells (FDCs) [22] and
on certain but not all fibroblast lineages [16]. IL-15 on FDCs has
been described to promote B cell survival and proliferation [22].
IL-15 on fibroblasts from human spleen regulates NK cell
differentiation from blood CD34+ progenitors [33] and IL-15 on
bone marrow fibroblast-like stromal cells contributes to T cell
Figure 5. VCAM-1 and BAFF facilitate the effect of IL-15 on B
cell survival and upregulate B cell IL-15R expression. A. Surface
expression of VCAM-1 and BAFF on non-permeabilized RASFib, OASFib
or dermal fibroblasts. Top panels: representative flow cytometry
histograms. Lower panels: bar histograms showing the mean and SD
of the MFI (mean fluorescence intensity) of all tested RASFib cell lines
(n = 10), OASFIb lines (n = 10) and dermal fibroblast lines (n = 5) B. Effect
of rhBAFF (1–400 ng/ml) on isolated B cells cultured alone for 6 days.
Each point represents the mean and SD of 15 subjects. C. Percentage of
viable B cells cultured for 6 days in plain medium, medium with rhIL-15
or rhBAFF, VCAM-1-coated plates, rhIL-15 plus BAFF or rhIL-15 plus
VCAM-1. *p,0.05 vs medium; {p,0.05 vs same condition without rhIL-
15. D. Fold of induction of IL-15Ra, b and c on B cells cultured for 6 days
with rhBAFF or rhVCAM-1, as determined by cytometry and referred to
freshly isolated cells. E. Percentage of viable B cells cultured for 6 days
in medium, or cocultured with RASFib in the absence or presence of
anti-VCAM-1 or anti-BAFF antibodies, in combination or not with an
anti-IL15 antibody, with or without rhIL-15. *p,0.05 vs B cells cultured
in medium; {p,0.05 vs same condition without rh IL-15; ¥p,0.05 vs
same condition without anti-VCAM-1 or anti-BAFF antibodies. 1 p,0.05
vs same condition without anti-IL15. F. Fold of induction of IL-15R a, b
and c on B cells cocultured for 6 days with RASFib, with or without anti-
VCAM-1 or anti-BAFF antibodies, as determined by cytometry and
referred to freshly isolated B cells. *p,0.05 vs B cells cocultured with
RASFib without antibodies. Each point represents the mean/SD of 15
subjects. G. Effect of VCAM-1 or BAFF neutralizing agents on the
survival of B cells cocultured with OASFib or dermal fibroblasts. Each
point represents the mean and SD of 15 subjects. * p,0.05 vs B cells
cultured alone in plain medium.
doi:10.1371/journal.pone.0040620.g005
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recruitment and expansion in aplastic anemia [34]. We previously
reported that constitutively expressed IL-15 on the surface of
RASFib induces T cell activation and cytokine secretion through
direct cell contact [16] and is also able to modulate the equilibrium
between regulatory and responder CD4 T cells [17]; in contrast,
resting OASFib or dermal fibroblasts do not modulate T cell
biology, consistent with their lack of constitutive surface IL-15
expression [16,17].
Our initial hypothesis stated that RASFib surface IL-15 plays an
important role in promoting contact-dependent survival of B cells.
This was confirmed in experiments with neutralizing antibodies to
IL-15, IL-15Ra and with a soluble IL15Ra-Fc chimera. Interest-
ingly, whereas the effect of RASFib on B cell survival and
differentiation was downmodulated by IL-15 neutralizing agents
and upregulated by rhIL-15, rhIL-15 itself did not significantly
modify the survival of isolated peripheral blood B cells from
healthy controls. This is in agreement with previously reported
results indicating that resting B cells are not responsive to
exogenous rhIL-15 in the absence of a facilitating stimulus [21].
Indeed, we observed that RASFib themselves seemed to
facilitate the response to IL-15 through an upregulation of B cell
IL-15R chains that was mediated by initially unidentified factors.
Subsequent experiments indicated that BAFF and VCAM-1, two
B cell survival molecules expressed on the surface of RASFib, are
able to mediate IL-15R upregulation. This is consistent with
published reports describing a facilitating effect of VCAM-1 and of
BAFF on the function of B cell surface molecules [35,36] and
indicates that cooperation among various surface molecules is
responsible for the effect of RASFib on B cell survival. In fact,
observations from other authors describing the action of RASFib
on B cells, had noted that functional blocking of BAFF or of
VCAM-1 had a partial effect on downregulating B cell survival [8–
11], which suggested the contribution of additional B cell trophic
factors. We also observed that OASFib and dermal fibroblasts,
which do not constitutively express IL-15, VCAM-1 nor BAFF on
the cell membrane, were significantly less effective than RASFib at
promoting B cell survival, and neutralization of these agents had
no effect on the survival of cocultured B cells.
Importantly, experiments with transwell inserts and with
coculture supernatants indicated that soluble factors are not
sufficient to prolong B cell survival in our system, which is in
agreement with published observations [9]. Soluble IL-15 was not
detected in coculture supernatants; in addition, very low amounts
of soluble BAFF were present, and exogenous rhBAFF could not
halt B cell apoptosis at concentrations below 10 ng/ml, consistent
with previous work supporting the necessity of direct cell contact
for the effect of BAFF expressed on RASFib to take place
[12,13].Peripheral blood B cells from RA patients have been
shown to display several specific features [37–39] indicative of a
preactivated state. We observed for the first time an upregulated
expression of IL-15R a, b and c chains on memory B cells from
the peripheral blood of early RA patients. This resulted in an
enhanced response to rhIL-15 and to RASFib IL-15, with further
improved survival rates when cocultured ex vivo with RASFib.
Interestingly, when memory B cells from 8 of the 15 early RA
patients were re-examined in a follow-up visit, after remission had
been achieved with treatment (oral methotrexate with or without
low-dose prednisone), their IL-15R expression and their behaviour
in coculture with RASFib were no longer different from healthy
controls.
Conclusions
In summary, the results presented herein indicate that RASFib
IL-15 expression may be an important contributor to the initiation
and perpetuation of the inflammatory process in RA. Under
physiological conditions, B cells continuously traffick through
lymphoid and non-lymphoid organs [40,41], and B cell persistence
in tissues is conditioned by local stromal factors [42]. The
constitutive IL-15 expression on the surface or RASFib, cooper-
ating with VCAM-1 and BAFF, is likely to create a specific
microenvironment promoting B cell fitness. This may provide a
survival niche favoring the persistence of B cells in the synovium
despite intensive therapy with biologicals such as anti-TNF and
anti-CD20 mAbs.
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Figure 6. Memory B cells from the peripheral blood of early RA patients demonstrate and upregulated IL-15R expression together
with superior survival rates in response to rhIL-15 and in coculture with RASFib. A. Surface expression of IL-15 receptor a, b and c chains
on memory B cells from healthy controls (n = 15) (black bars), from early RA patients (n = 15) (open bars), and from 8 early RA patients who donated
blood for a second time after achieving remission (grey bars), as determined by flow cytometry of non-permeabilized cells, and expressed as mean
fluorescence intensity (MFI). Each bar represents the mean and SD of 15 or 8 subjects. *p,0.05 vs healthy controls. B. Percentage of viable B cells
cultured for 6 days in plain medium, or in medium supplemented with rhIL-15, or cocultured with RASFib in plain medium, or cocultured with RASFib
in the presence of a neutralizing anti-IL-15 mAb. Black bars represent B cells from healthy controls (n = 15), open bars represent B cells from early RA
patients (n = 15) and grey bars represent B cells from 8 early RA patients who donated blood for a second time after achieving remission. Each bar
represents the mean and SD of 15 or of 8 subjects. *p,0.05 vs B cells cultured in plain medium. {p,0.05 vs B cells from healthy controls; ¥p,0.05 vs
B cells cocultured with RASFib in the absence of an anti-IL-15 neutralizing antibody.
doi:10.1371/journal.pone.0040620.g006
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